PDRN(PolyDeoxyRiboNucleotide) 100403-24-5/9007-49-2

98% up by HPLC, Injection Grade

Inquire now

Product categories

New Products

Product Details

Product Information

Product name	PDRN(PolyDeoxyRiboNucleotide)
CAS No.	100403-24-5/9007-49-2
Quality Standard	98.5% up by HPLC
Appearance	White to pale yellow powder

COA

Test Items	Specifications	Results
Appearance	White to pale yellow powder	Conform
Identification	Ratio of UV absorbance at 260nm and 280nm should be 1.5-2.0	1.78
Solubility	Soluble in water	Conform
pH (1%Aqueous Solution)	5.0-9.0	7.0
Loss on Drying	≤15%	7.2%
Average Molecular Weight	≤650KDa/1050bp	<650KDa/1050bp
Assay (dry goods,HPLC )	≥95.0%	98.9%
Cd	≤5mg/kg	Conform
Pb	≤10mg/kg	Conform
Hg	≤1mg/kg	Conform
As	≤2mg/kg	Conform
Total of Bacteria	≤500cfu/g	<50cfu/g
Mold and Yeast	≤100cfu/g	<50cfu/g
PAeruginosa	Negative	Not detected
E.coli	Negative	Not detected
S.aureus	Negative	Not detected
Conclusion	It conforms to Enterprise standard

Usage

PDRN is a DNA fragment extracted and purified from salmon sperm DNA through specific processes. It exhibits high biocompatibility and safety and is widely used in the field of regenerative medicine.

Core Mechanisms of Action

The primary effects of PDRN are regeneration and repair and anti-inflammation , mainly achieved through the following mechanisms:

1. Activation of Adenosine A2A Receptor:

This is the primary pathway through which PDRN acts. After entering the human body, PDRN is taken up by cells and degraded, producing a significant amount of adenosine. Adenosine binding to the A2A receptor on cell surfaces leads to:

• Significant promotion of tissue regeneration and repair : Stimulates the proliferation of fibroblasts, collagen, and vascular endothelial cells, accelerating the healing of soft tissues, bones, and cartilage.

• Powerful anti-inflammatory effects : Inhibits the release of multiple pro-inflammatory factors, reducing inflammatory responses and pain.

2. Providing Raw Materials for Nucleotide Synthesis :

As the basic structural unit of DNA/RNA, PDRN supplies essential "building blocks" for damaged or metabolically active cells (e.g., stem cells, immune cells), promoting cell proliferation and tissue regeneration.

3. Upregulation of Growth Factor Expression:

Studies show that PDRN can upregulate the expression of key growth factors (e.g., VEGF vascular endothelial growth factor, EGF epidermal growth factor), thereby promoting angiogenesis (supplying oxygen and nutrients to damaged tissues) and cell regeneration.

In summary, PDRN is a bioactive substance derived from natural salmon DNA. Through its dual mechanisms of activating repair signals (via A2A receptors) and supplying raw materials for repair nucleotides, it demonstrates remarkable effects in tissue regeneration, wound healing, and anti-inflammation across various fields. From widely known applications in aesthetic anti-aging to specialized treatments for refractory ulcers and orthopedic conditions, PDRN is becoming an increasingly important tool in regenerative medicine.

Hot Tags : PDRN Polydeoxyribonucleotide Polynucleotide DEOXYRIBONUCLEIC ACID HERRING SPERM DNA Salmon DNA

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Subject : PDRN(PolyDeoxyRiboNucleotide) 100403-24-5/9007-49-2

Related Products

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.